No description available.

No description available.

No description available.

Wong Kin Yee. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (leaves 151-166). / Abstracts in English and Chinese. / Chapter (I) --- ABSTRACT (IN ENGLISH) --- p.i / Chapter (II) --- Abstract (in Chinese) --- p.iv / Chapter (III) --- ACKNOWLEDGEMENTS --- p.vii / Chapter (IV) --- PERSONAL CONTRIBUTION TO THE WORK --- p.ix / Chapter (V) --- PUBLICATIONS --- p.x / Chapter (VI) --- TABLE OF CONTENTS --- p.xi / Chapter (VII) --- List of Abbreviations --- p.xvi / Chapter (VIII) --- LIST OF FIGURES --- p.xx / Chapter (IX) --- LIST OF TABLES --- p.xxii / Chapter Section 1: --- GENERAL INTRODUCTION / Chapter CHAPTER 1 --- General Introduction of Atopic Dermatitis --- p.1-8 / Chapter 1.1. --- Definition of Atopic Dermatitis --- p.1 / Chapter 1.2. --- Epidemiology and Classification --- p.3 / Chapter 1.3. --- Factors Provoking Flares of AD / Chapter 1.3.1. --- Genetics --- p.5 / Chapter 1.3.2. --- "Allergens-Food Allergens, Aeroallergens and Autoallergens" --- p.6 / Chapter 1.3.3. --- Microbial Colonization: Staphylococcus Aureus (S. aureus) --- p.7 / Chapter CHAPTER 2 --- Measurements of AD Severity and Quality of Life Impairment --- p.9-14 / Chapter 2.1. --- Scoring of Atopic Dermatitis severity and the SCORing Atopic Dermatitis (SCORAD) Index --- p.9 / Chapter 2.2. --- Quality of life Measurement --- p.10 / Chapter 2.3. --- The Children's Dermatology Life Quality Index --- p.11 / Chapter CHAPTER 3 --- Management of AD --- p.15-19 / Chapter 3.1. --- Current Management of AD and Their Drawbacks --- p.15 / Chapter 3.2. --- Traditional Chinese Herbal Medicne (TCHM) / Chapter 3.2.1. --- General Principle of TCHM --- p.17 / Chapter 3.2.2. --- Side Effects of Using TCHM --- p.18 / Chapter 3.2.3. --- Literature Reviews of TCHM Use in Treating AD --- p.18 / Chapter CHAPTER 4 --- The Pentaherbs Formula for AD Treatment --- p.20-26 / Chapter 4.1. --- Pilot study: Pentaherbs Capsule as Treatment Option of AD Children --- p.20 / Chapter 4.2. --- Literature Review: Nature of Five Herbs / Chapter 4.2.1. --- PHF as Treatment Option of AD under TCHM Concepts --- p.22 / Chapter 4.2.2. --- PHF as Treatment Option of AD from Modern Research Literature --- p.22 / Chapter CHAPTER 5 --- Pathobiology of Atopic Dermatitis --- p.27-40 / Chapter 5.1. --- Nature of Complexity of Pathogenesis --- p.27 / Chapter 5.2. --- Skin barrier-impairment of epidermal barrier --- p.28 / Chapter 5.3. --- Biphasic T cell response in skin of AD --- p.29 / Chapter 5.4. --- Nature of Immunoglobulin-E and its Role in Atopic Dermatitis --- p.32 / Chapter 5.5. --- Innate Immunity Defect in AD --- p.33 / Chapter 5.6. --- Role of Superantigen in Pathogenesis of AD --- p.35 / Chapter 5.7. --- "Cytokines, Chemokines and Inflammatory Mediators in Pathogenesis of Atopic Dermatitis" / Chapter 5.7.1. --- Proinflammatory Cytokines --- p.37 / Chapter 5.7.2. --- Th1/Th2 Cytokines --- p.37 / Chapter 5.7.3. --- Chemokines --- p.38 / Chapter 5.7.4. --- Pruritus Mediators --- p.39 / Chapter Section 2: --- CLINICAL TRIAL OF PENTAHERBS / Chapter CHAPTER 1 --- Objective --- p.41 / Chapter CHAPTER 2 --- Materials and Methods (RCT) --- p.42-51 / Chapter 2.1. --- Materials / Chapter 2.1.1. --- SCORAD worksheet --- p.42 / Chapter 2.1.2. --- CDLQI questionnaire --- p.42 / Chapter 2.1.3. --- Allergic Rhinitis Score (ARS) --- p.43 / Chapter 2.1.4. --- ELISA Assay Kits --- p.43 / Chapter 2.1.5. --- EDTA blood collestion tubes --- p.43 / Chapter 2.2. --- Methods / Chapter 2.2.1. --- Design --- p.45 / Chapter 2.2.2. --- Intervention --- p.45 / Chapter 2.2.3. --- Treatment / Chapter 2.2.3.1 --- The Pentaherbs Formula --- p.45 / Chapter 2.2.3.2 --- Randomization --- p.48 / Chapter 2.2.3.3 --- Concomitant Treatment in Study Period --- p.48 / Chapter 2.2.4. --- Participants --- p.49 / Chapter 2.2.5. --- Outcome Measures --- p.50 / Chapter 2.2.6. --- Statistical Analysis --- p.50 / Chapter CHAPTER 3 --- Results (RCT) --- p.52-67 / Chapter 3.1. --- Demographics --- p.52 / Chapter 3.2. --- Drug Compliance --- p.55 / Chapter 3.3. --- Efficacy / Chapter 3.3.1. --- SCORAD Score --- p.56 / Chapter 3.3.2. --- Quality of Life Score --- p.56 / Chapter 3.3.3. --- Duration and Amount of CS Usage --- p.59 / Chapter 3.3.4. --- Amount of Antihistamine Usage --- p.61 / Chapter 3.3.5. --- Allergic Rhinitis Score --- p.61 / Chapter 3.3.6. --- Blood chemistry and Haematology --- p.63 / Chapter 3.3.7. --- Plasma TARC and BDNF level --- p.63 / Chapter 3.4. --- Tolerability --- p.65 / Chapter Section 3: --- IN VITRO STUDY OF PENTAHERBS / Chapter CHAPTER 1 --- Objectives and Study Design --- p.68 / Chapter CHAPTER 2 --- Materials and Methods (In vitro Study) --- p.69-86 / Chapter 2.1. --- Materials for in vitro study / Chapter 2.1.1. --- Preparation of the Water Extracts of PHF Capsules --- p.69 / Chapter 2.1.2. --- Endotoxin Assay --- p.69 / Chapter 2.1.3. --- Cell isolation and culture ofPBMC / Chapter 2.1.3.1 . --- Cell Isolation from Human Peripheral Blood --- p.70 / Chapter 2.1.3.2. --- Culture of Peripheral Blood Mononuclear Cells --- p.70 / Chapter 2.1.4. --- Trypan Blue Exclusion Assay --- p.72 / Chapter 2.1.5. --- [3H]-Thymidine incorporation Assay --- p.72 / Chapter 2.1.6. --- Supernatant Collection and ELISA --- p.72 / Chapter 2.1.7. --- RNA Extraction and RT-PCR / Chapter 2.1.7.1. --- Reagents for RNA Extraction --- p.73 / Chapter 2.1.7.2. --- Reagents for Reverse Transcription --- p.73 / Chapter 2.1.7.3. --- Reagents for Polymerase Chain Reaction --- p.74 / Chapter 2.1.7.4. --- Reagents for Gel Electrophoresis --- p.74 / Chapter 2.2. --- Methods / Chapter 2.2.1. --- Isolation and Culture PBMC / Chapter 2.2.1.1. --- Isolation of PBMC --- p.76 / Chapter 2.2.1.2. --- Culture of Isolated PBMC --- p.76 / Chapter 2.2.1.3. --- PHA/SEB Treatment --- p.77 / Chapter 2.2.2. --- Preparation of PHF Water Extracts and Endotoxin Level / Chapter 2.2.2.1. --- Hot Water Extraction --- p.78 / Chapter 2.2.2.2. --- Limulus Amebocyte Lysate Assay --- p.78 / Chapter 2.2.3. --- Study on the Cytotoxic and Mitogenic Effects of PHF on PBMC / Chapter 2.2.3.1. --- Trypan Blue Exclusion Assay --- p.80 / Chapter 2.2.3.2. --- [3H]-Thymidine Incorporation Assay --- p.80 / Chapter 2.2.4. --- Study on the Effect of PHF on PBMC Inflammatory Mediator Production / Chapter 2.2.4.1. --- Determination of Inflammatory Mediator Expression Levels by ELISA --- p.82 / Chapter 2.2.4.2. --- Semi-quantification of Inflammatory Mediator mRNA Levels by RT-PCR --- p.83 / Chapter 2.2.5. --- Statistical Analysis --- p.86 / Chapter CHAPTER 3 --- Results(In vitro) --- p.87-114 / Chapter 3.1. --- preparation of PHF Water Extracts and Endotxin Level --- p.87 / Chapter 3.2. --- Cytotoxicity Effect of PHF on PBMC --- p.88 / Chapter 3.3. --- Mitogenicity Effect of PHF on PBMC --- p.93 / Chapter 3.4. --- Effects of PHF on Expression of Inflammatory Mediators from PBMC Following Mitogen (PHA) Stimulation / Chapter 3.4.1. --- Effects of PHF on mRNA Expression of Inflammatory Mediators from PHA-stimulated PBMC --- p.98 / Chapter 3.4.2. --- Effects of PHF on Secretion of Inflammatory Mediators from PHA-stimulated PBMC --- p.101 / Chapter 3.5 --- Effects of PHF on Expression of Inflammatory Mediators from SEB-stimulated PBMC / Chapter 3.5.1. --- Effects of PHF on mRNA Expression of Inflammatory --- p.106 / Chapter 3.5.2. --- Effescts of PHF on secretion of inflammatory Mediatorsfrom SEM-Stimulated PBMC --- p.109 / Chapter 3.6. --- Summarization of Effects of PHF on Expression of Inflammatory Mediators from PHA- and SEB-stimulated PBMC / Chapter 3.6.1. --- Mitogen (PHA) Stimulation --- p.114 / Chapter 3.6.2. --- Superantigen (SEB) Stimulation --- p.114 / Chapter Section 4: --- DISCUSSIONS / Chapter CHAPTER 1 --- Discussions on RCT of PHF --- p.115-122 / Chapter 1.1. --- Clinical Efficacy and Tolerability of PHF for Treatment of Children AD: a RCT study / Chapter 1.2. --- Efficacy of PHF for Treatment of Children with AD --- p.117 / Chapter 1.3. --- Safety and Tolerability of PHF Use for Treatment of Children with AD --- p.119 / Chapter 1.4. --- Rounding up --- p.121 / Chapter CHAPTER 2 --- Discussions on In vitro Immunomodulatory Activities of PHF --- p.123-130 / Chapter 2.1. --- General Effects of PHF on PBMC --- p.123 / Chapter 2.2. --- Effects of PHF on Inflammatory Mediators Expression in PBMC --- p.124 / Chapter CHAPTER 3 --- Limitations of the Present Study --- p.131-132 / Chapter Section 5: --- CONCLUSIONS AND FUTURE PROSPECTS / Chapter CHAPTER 1 --- Conclusions --- p.133 / Chapter CHAPTER 2 --- Future Prospects --- p.134-135 / Chapter Section 6: --- APPENDICES / Appendix1 --- p.137 / Appendix2 --- p.142 / Appendix3 --- p.149 / Chapter Section 7: --- BIBLIOGRAPHY --- p.151-166

The adaptor protein Shb has been implicated in the signaling of several tyrosine kinase receptors and previous studies have suggested a role for Shb in the signal transduction of T cells. Shb associates with the T cell receptor (TCR) and partakes in the signal propagation of activated T lymphocytes. In order to explore Shb’s influence on TCR signaling in vivo, T cell development and function was studied in a Shb knockout mouse. The loss of Shb led to aberrant TCR signaling in both thymocytes and peripheral CD4+ TH cells, with elevated basal phosphorylation of key components in the signal cascade. Shb was found to be dispensable for thymocyte development, but its absence resulted in a TH2 bias in in vitro stimulated peripheral CD4+ TH cells. As imbalances in TH2 responses are linked to allergic diseases, we further explored Shb’s role in immune regulation in a mouse model of atopic dermatitis. Shb knockout mice exhibit more aggravated signs of atopic dermatitis, including increased immune cell recruitment to the affected areas and elevated mRNA levels of typical TH2 cytokines. The effect of Shb on hematopoiesis in general was determined by examining populations of long-term hematopoietic stem cells (LT-HSCs) and hematopoietic progenitor cells in bone marrow of Shb knockout and wild type mice. Shb deficient bone marrow was found to contain significantly fewer relative numbers of LT-HSCs due to a proliferative defect. The reduced cell cycle activity of Shb LT-HSCs could further be linked to an abnormal regulation of the focal adhesion kinase/Rac1/p21-activated kinase pathway. Since alterations in LT-HSC proliferative abilities may have implications for leukemia development, BCR-Abl induced myeloid neoplasia was investigated in the absence of Shb. Shb deficiency confers a more aggressive progression of BCR-Abl induced myeloid neoplasia characterized by an increased peripheral blood neutrophilia and a deregulated cytokine profile. In addition, focal adhesion kinase and STAT3 signaling is hyperactivated in Shb knockout leukemic cells. In conclusion, Shb appears to be a multifunctional signaling mediator that controls several responses in hematopoietic cells, under homeostatic as well as disease conditions.

ABSTRACT Introduction and Rationale: Atopic Dermatitis (AD) is a common skin condition, characterized by markedly pruritic eczematous lesions, that most often presents in childhood. The majority of children diagnosed with AD will have mild disease and will first present with symptoms to a primary care provider (PCP), however approximately 85% of pediatricians only provide limited initial care followed by a referral to dermatology (Eichenfield et al., 2015). While there are specialty care based treatment guidelines for childhood AD, there are no guidelines available that specifically address primary care management of childhood AD. Purpose and Objective: The primary purpose of this DNP project is to develop an evidence-based clinical practice guideline (CPG) for pediatric PCPs. The secondary purpose is to develop a corresponding atopic dermatitis action plan (ADAP) to be used by children and parents. The objective is to equip PCPs to better manage children with AD in the primary care setting and to guide patients and parents in the importance of daily control measures and in the individualized treatment plan prescribed by the PCP. Methods: The Appraisal of Guidelines for Research & Evaluation II (AGREE II) framework and Social Cognitive Theory (SCT) serve as the theoretical frameworks for CPG and ADAP development. The American Academy of Pediatrics (AAP) process for evidence based policy setting is used as a model for key action statement development. Results: Evaluation of the CPG was completed using the AGREE II tool, a reliable and validated tool for evaluating CPGs. Five of the six domains evaluated, yielded combined scores of at least 90%, with one domain a combined score of 63%. The overall standard deviation was 0.58, indicating an overall low level of user discrepancy Additions and revisions were made based on the results of the AGREE II evaluation scores with specific emphasis on the lowest scoring domain. Conclusion: This DNP Project identified the need for a CPG specific to pediatric primary care. A CPG with accompanying ADAP was developed and evaluated using the AGREE II tool. The CPG was found to meet the recommended standards and recommended for use in pediatric primary care.

Human T lymphotropic virus type -1 (HTLV-1) infections are important causes of mortality and morbidity in endemic areas worldwide. There is neither a vaccine specific for the virus nor satisfactory treatment for the associated malignancy or inflammatory syndromes. HTLV-1 associated infective dermatitis (IDH) is a chronic dermatitis that has been observed in a variable proportion of HTLV-1 infected children. IDH may serve as an early clinical marker for HTLV-1 and an indicator of increased risk for developing other HTLV-1 associated conditions such as adult T cell leukaemia/lymphoma (ATLL) and HTLV-1-associated myelopathy or transient spastic paraparesis (HAM/TSP). However the mechanisms underlying IDH and the relationships with HAM/TSP and ATLL are poorly understood. We undertook skin biopsies from 14 cases with IDH, and controls which included five asymptomatic carriers (ACs) and 18 healthy uninfected individuals from South Africa. We conducted clinical assessments, proviral load, allergen-specific IgE, peripheral blood and cutaneous T cell and virological analyses. We obtained relevant clinical history and examined all cases and controls based on a pre-formed questionnaire. Despite the partial clinical similarities with atopic dermatitis, the individuals with IDH did not have an increased incidence of atopic disease including asthma or rhinitis. Furthermore house dust mite-specific IgE levels were not elevated in the cases compared to the controls, suggesting that atopy is not a predisposing factor for the development of IDH in HTLV-1 infected individuals. Circulating proviral load was significantly higher in those with IDH compared to asymptomatic carriers and skin biopsy revealed acanthosis, and lymphocytic epidermotropism associated with a superficial perivascular and periadnexal lymphocytic infiltration of CD8+, and CD4+ T cells. Furthermore IDH associated with an infiltrate of epidermal and dermal FoxP3+ T cells and lesional down-regulation of filaggrin expression compared to non-lesional skin. We did not observe an elevation of pro-inflammatory cytokines in the sera of individuals with IDH compared to the controls. We investigated integration patterns in the skin and blood of 10 cases with IDH, and two asymptomatic carrier (AC) individuals from South Africa. We first showed that the virus is present in the skin at high levels (total mean levels of 47.09 proviral copies per 1000 cells) as comparable to that which has been observed in blood (total mean levels 137 proviral copies per 1000 cells). Using a high throughput Illumina sequencing system in collaboration with Professor Bangham, we mapped and quantified the relationship between oligoclonal proliferation of HTLV-1 infected T cells in the skin and blood of IDH patients. It was found that in IDH, a selective outgrowth of certain clones is favoured, supporting the possibility of skin-specific factors exerting positive selection on proliferation. In IDH, there was not a preferential integration of the provirus in transcriptionally active regions of the gene sites, as had been observed in other HTLV-1 associated conditions. These observations imply that the selection forces that favour oligoclonal proliferation of HTLV-1+ T cells differ fundamentally between simple HTLV-1 infection and other events associated with the dermatitis. In conclusion, these data show that HTLV-1 is not associated with an atopic diathesis. Given the lack of elevated pro-inflammatory cytokines and presence of a cutaneous infiltrate of FoxP3+ T cells, the findings suggest that high levels of HTLV-1 replication promotes a regulatory environment leading to filaggrin down-regulation, cutaneous susceptibility to infection, and secondary inflammatory skin disease. Viral integration patterns would support the presence of skin-specific positive selection, perhaps eventually leading to expansion of particular clones with the potential to develop towards ATLL. It remains to be explained whether the high viral load in IDH changes over time, more specifically in the steps leading to ATLL.

A qualidade de vida tem sido objeto de muito interesse nos últimos tempos. A Qualidade de Vida Relacionada à Saúde é considerada como um indicador de saúde, que aborda aspectos físicos, mentais e sociais relativos à saúde. Para sua mensuração necessita-se de instrumentos válidos e confiáveis desenvolvidos ou adaptados para a cultura alvo. Condições crônicas dermatológicas têm sido associadas ao declínio da qualidade de vida dos indivíduos acometidos por estas. O objetivo deste estudo foi adaptar culturalmente para o Brasil e obter as características psicométricas iniciais do instrumento DISABKIDS®-MDA para avaliação da qualidade de vida relacionada à saúde de crianças/adolescentes com Dermatite Atópica e seus pais/cuidadores, instrumento que possui 12 itens e duas dimensões, impacto e estigma. A pesquisa consistiu de uma investigação metodológica quantitativa, que incluiu uma amostra de 70 crianças/adolescentes brasileiros com Dermatite Atópica, na faixa etária de 8 a 18 anos, e seus responsáveis, recrutados no Serviço de Dermatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, na cidade de São Paulo, entre os meses de abril e setembro de 2009. O processo abrangeu as fases de tradução-retrotradução, validação semântica e teste piloto, por meio de análise estatística apropriada. A validação semântica mostrou boa aceitação do instrumento pelos participantes, o qual foi considerado como muito bom e composto por itens de fácil compreensão. A confiabilidade de consistência interna foi satisfatória, com coeficiente Alfa de Cronbach aceitáveis para as dimensões constantes no instrumento (0,7024/0,8124 e 0,7239/0,8604). A análise MAP para validade convergente mostrou valores maiores que 0,30 para todos os itens. Quanto à validade discriminante, a análise revelou resultados satisfatórios. A concordância entre as versões self e proxy foi acessada pelo coeficiente de Correlação Intra-Classe, com valores de 0,8173 para impacto e 0,7629 para estigma. Diante dos resultados encontrados neste estudo considera-se que o instrumento DISABKIDS®-MDA possa vir a ser utilizado por pesquisadores brasileiros depois de finalizado seu processo de validação no país, por seus resultados iniciais apontarem ser um instrumento válido e confiável. / Quality of Life has been object of many interesting nowadays. Health Related Quality of Life is considered as a health indicator, which approaches physical, mental and social aspects. Its measurement involves instruments with validity and reliability developed or adapted to a specific culture. Dermatologic chronic conditions has been associated with patients quality of life decrease. The aim of this study was to do the cultural adaptation to Brazil and to obtain DISABKIDS®-MDAs preliminary psychometric properties to measurement of health related quality of life of children/adolescents with Atopic Dermatitis and their parents/caregivers. The instrument has 12 items and two dimensions, impact and stigma. The research consisted of a quantitative methodological investigation, that included a sample of 70 Brazilian children/adolescents with Atopic Dermatitis, aged 8 to 18, and their parents/caregivers, recruited at Dermatology Service from Clinic Hospital from College of Medicine from University of Sao Paulo, at Sao Paulo, between April and September of 2009. The procedure comprised translation, back-translation, linguistic validation and pilot test, with appropriate statistic analysis. On the linguistic validation the instrument was well accepted by the participants, and it was considered very good and has comprehensible items. Reliability of internal consistency was adequate, with Cronbachs Alpha acceptable to instruments dimensions (0,7024/0,8124 and 0,7239/0,8604). The MAP analysis to convergent validation displayed values higher than 0,30 for all items. In relation to discriminant validation, the analysis presented acceptable outcomes. The agreement between self and proxy versions was accessed by ICC, with values of 0,8173 to impact and 0,7629 to stigma. By the outcomes from this research, DISABKIDS®-MDA, after its complete validation procedure at the country, may be used by Brazilian researchers, once its initial outcomes appoint to be a valid and reliable instrument.

INTRODUÇÃO: A dermatite atópica é uma doença inflamatória crônica da pele que possui alta prevalência e etiopatogenia multifatorial. Os ácaros são alguns dos desencadeadores das crises desta enfermidade. OBJETIVO: avaliar a freqüência de positividade ao teste de contato, utilizando extratos do ácaro Aleuroglyphus ovatus em doentes com dermatite atópica, comparando-a à dos doentes portadores de alergia respiratória e à dos indivíduos sem atopia. MÉTODOS: Cento e vinte e quatro indivíduos (48 doentes com dermatite atópica, 47 com alergia respiratória e 29 sem atopia) foram avaliados através do teste de contato contendo extrato de Aleuroglyphus ovatus nas concentrações de 0,1%, 0,5%, 1,0%, 1,5%, 2,0%. O teste de puntura com leitura imediata (“prick test") e a dosagem da IgE sérica também foram avaliados. RESULTADOS: seis doentes com dermatite atópica, 4 com alergia respiratória e 1 indivíduo sem atopia responderam positivamente ao teste de contato alérgico com Aleuroglyphus ovatus. Não houve diferença estatística significativa entre os grupos estudados. CONCLUSÃO: O Aleuroglyphus ovatus possui papel relativo na elicitação das crises de dermatite atópica, podendo o teste de contato alérgico com Aleuroglyphus ovatus ser usado em caso de dúvida no diagnóstico etiológico. / INTRODUCTION: Atopic dermatitis is a chronic, inflammatory disease of the skin with high prevalence and complex etiopathogenesis. Mites are known to cause flares of this disease. OBJECTIVE: Evaluation of the epicutaneous test response with Aleuroglyphus ovatus antigen in patients with atopic dermatitis. METHODS: One hundred and twenty four subjects were patch tested with Aleuroglyphus ovatus antigen in concentrations of 0.1%, 0.5%, 1.0%, 1.5%, 2.0%. Forty eight patients with atopic dermatitis, 47 with respiratory allergy and 29 healthy subjects were studied. Prick test and total serum IgE were also evaluated. RESULTS: six patients with atopic dermatitis, 4 with respiratory allergy and 1 healthy subject had positive responses to Aleuroglyphus ovatus atopy patch test. No statistical differences among the studied groups were found. CONCLUSION: This mite must have a relative role in the atopic dermatitis flares and Aleuroglyphus ovatus atopy patch test should be reserved for etiopathogenic uncertainties cases.

A Qualidade de Vida Relacionada à Saúde é definida como um indicador de saúde, que compreende fatores físicos, mentais e sociais e os impactos que uma determinada condição de saúde pode trazer à vida do indivíduo. Instrumentos válidos e fidedignos são ferramentas de grande valia para a mensuração deste construto. A Dermatite Atópica é uma condição crônica dermatológica associada a inúmeros prejuízos nos diversos aspectos da vida de uma pessoa, especialmente em crianças e adolescentes. O objetivo deste estudo foi validar para o Brasil o instrumento DISABKIDS®- Módulo Dermatite Atópica, para mensuração da Qualidade de Vida Relacionada à Saúde de crianças e adolescentes, com Dermatite Atópica, em idade escolar. O Instrumento compreende 12 itens e duas dimensões, Impacto e Estigma, e duas versões, self e proxy. A amostra foi composta por 200 sujeitos, 100 crianças e adolescentes brasileiros com Dermatite Atópica, entre 8 a 18 anos de idade, e seus pais ou cuidadores, recrutados no Serviço de Dermatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, na cidade de São Paulo, em dois momentos, entre os meses de abril e setembro de 2009 e julho de 2012 a junho de 2013. A fidedignidade do instrumento foi satisfatória tanto em relação à sua consistência interna, mensurada segundo o Coeficiente Alfa de Cronbach (self: ?Cronbach = 0,855; 0,853 e proxy: ?Cronbach = 0,905; 0,858, dimensões Impacto e Estigma, respectivamente), quanto à sua reprodutibilidade, mensurada segundo Coeficiente de Correlação Intra-Classe (self: ICC = 0,952; 0,971 e proxy; ICC = 0,960; 0,972, dimensões Impacto e Estigma, respectivamente). A análise Multitraço-multimétodo para teste de validade convergente mostrou valores de coeficientes de correlação lineares de Pearson entre cada item e sua dimensão maiores que 0,40. Quanto à validade discriminante, a análise revelou resultados igualmente satisfatórios, com índices de ajuste iguais a 87,5% e 100% para a versão self e a 75% e 100% para a versão proxy, dimensões Impacto e Estigma, respectivamente. Houve concordância entre as versões self e proxy, com valores para Coeficiente de Correlação Intra-Classe iguais à 0,610 para a dimensão Impacto e 0,595 para a dimensão Estigma. A Análise Fatorial Confirmatória mostrou que o instrumento adaptado para o Brasil manteve a estrutura assumida para o construto no instrumento original (self: RMSEA=0,083; CIF=0,932 e proxy: RMSEA=0,098; CIF=0,936). Considera-se que o instrumento DISABKIDS®- Módulo Dermatite Atópica encontra-se validado para crianças e adolescentes brasileiros em idade escolar com diagnóstico de Dermatite Atópica apresentando características de boa fidedignidade de consistência interna e reprodutibilidade, boa validade de construto convergente e discriminante, boa correlação e entre as versões self e proxy, e com a estrutura fatorial do construto inalterada em relação à inicialmente assumida no instrumento europeu. / The Health-related Quality of Life is defined as an indicator of health, including physical, mental and social factors and the impacts that a certain health condition can bring to an individual\'s life. Valid and reliable instruments are valuable tools for the measurement of this construct. Atopic Dermatitis is a chronic dermatological condition associated with numerous losses in various aspects of a person\'s life, especially in children and adolescents. The objective of this study was to validate for Brazil the DISABKIDS® - Atopic Dermatitis Module, for measurement of Health- related Quality of Life of children and adolescents, with atopic dermatitis, school aged. The instrument comprises 12 items and two dimensions, Impact and Stigma and two versions, self and proxy. The sample was composed of 200 people, 100 Brazilian children and adolescents with atopic dermatitis, between 8 to 18 years of age, and their parents or caregivers, recruited at the Dermatology Service of the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, in the city of Sao Paulo, in two moments, between the months of April and September 2009 and July 2012 to June 2013. The reliability of the instrument was satisfactory in relation to its internal consistency, measured according to Cronbach\'s alpha Coefficient (self: ?Cronbach = 0,855; 0,853 e proxy: ?Cronbach = 0,905; 0,858, dimensions Impact and Stigma, respectively), as to its reproducibility, measured according to Intra-class Correlation Coefficient (self: ICC = 0,952; 0,971 e proxy; ICC = 0,960; 0,972, Impact and Stigma dimensions, respectively). Multitraço- Multimethods Analysis to convergent validity test showed values of Pearson Linear Correlation Coefficients between each item and its size greater than 0.40. As to the validity, discriminant analysis showed also satisfactory results with adjustment indexes equal 87,5 and 100 for self and 75 and 100 for the proxy version, dimensions, Impact and Stigma, respectively. There was agreement among self answers and proxy, with values for Intra-class Correlation Coefficient equal to 0,610 Impact dimension and 0,595 Stigma. The Confirmatory Factor Analysis showed that the instrument adapted to Brazil kept the structure assumed for the original instrument (self: RMSEA=0,083; CIF=0,932 e proxy: RMSEA=0,098; CIF=0,936). It is considered that the DISABKIDS® - Atopic Dermatitis Module is validated for Brazilian children and adolescents of school age with a diagnosis of Atopic Dermatitis presenting features of good internal consistency for reliability and reproducibility, good discriminant and convergent construct validity, good correlation and between self and proxy versions, and with the factorial structure of the construct unchanged in relation to the initially assumed in the European instrument